Systemic Inflammation

Systemic inflammation is a crucial factor associated with a wide range of diseases, including viral infections like coronaviruses. Inflammatory responses aim to protect the host against a pathogen's attack. However, in severe cases, a hyper-active inflammatory response can lead to tissue damage and organ failure. In the context of coronavirus infections, systemic inflammation is a hallmark feature observed in patients. Pro-inflammatory cytokines like IL-1?, IL-6, and TNF? are elevated in infected patients, causing a cytokine storm, which results in damage to the lungs and other organs. Severe cases of COVID-19 are believed to be a result of this cytokine storm, where the abundance of these inflammatory mediators leads to acute respiratory distress syndrome (ARDS). Several studies have explored the use of anti-inflammatory agents like steroids and cytokine inhibitors in COVID-19 treatment, with varying outcomes. The use of these agents is aimed at dampening the immune response, thereby reducing the severe complications associated with viral infections. While steroids have shown some benefit in reducing mortality in severe COVID-19 cases, cytokine inhibitors have shown mixed results. In conclusion, systemic inflammation is an essential factor in COVID-19 pathogenesis. Novel therapeutic strategies targeting inflammatory pathways may be useful in treating severe cases of COVID-19, although further investigation is needed in this regard.